Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2014 May 13;13(6):1567–1577. doi: 10.1158/1535-7163.MCT-13-1023

Figure 6.

Figure 6

Treatment of mice with B-1239. Top, Schematic of in vivo treatment with 10 mg/kg B-1239, control 10 mg/kg human IgG or combined with 75 mg/kg nilotinib. Bottom, Percentage of human CD19+ CD10+ ALL cells as detected by FACS in blood, bone marrow and spleen of NSG leukemic mice and spleen weights of control and treated mice on d22. *p<0.05, **p<0.01, ***p<0.001; all comparisons with control. Nil versus nil+ B-1239, n.s. One of two independently performed experiments.